Pfizer Inc.
COMBINATION OF A CDK INHIBITOR AND A PIM INHIBITOR
Last updated:
Abstract:
This invention relates to combination therapies comprising a cyclin dependent kinase (CDK) inhibitor, in particular a CDK4/6 inhibitor, and a proviral integration site for Moloney murine leukemia virus (PIM) inhibitor, and associated pharmaceutical compositions, methods of treatment, and uses.
Status:
Application
Type:
Utility
Filling date:
31 Jan 2020
Issue date:
28 Apr 2022